Apollo Therapeutics

Apollo Therapeutics

A transformative idea for transformative medicines

Founded 2016 59 employees Series C Total: $313.50M Biopharma, Biotechnology +2

Apollo Therapeutics is a burgeoning biopharmaceutical company that is rapidly advancing a robust pipeline of potentially transformative therapeutic programs based on breakthrough discoveries. Founded in 2016, the company's innovative model was created in late 2015 by three world-leading universities - Cambridge, Imperial College London, and University College London - in partnership with AstraZeneca, GlaxoSmithKline, and Johnson & Johnson Innovation. The company's vision is encapsulated in their slogan, "A transformative idea for transformative medicines." With a vision to bring new treatments to the market, Apollo Therapeutics is focusing on scaling a robust and potentially transformative pipeline, with over 15 therapeutic programs in development today across oncology, major inflammatory disorders, and rare diseases. Their approach revolves around deep relationships with world-leading universities and scientists, enabling them to identify programs with strong biological hypotheses and potential to become meaningful new treatment options. They have a centralized team of drug development 'architects' and subject matter experts who rigorously evaluate therapeutic programs in an objective, data-driven manner - prioritizing critical experiments to de-risk programs early, hence ensuring capital efficiency. The company's growth is fueled by a $33.50M Series C investment at 02 January 2024, led by Patient Square Capital, Rock Springs Capital, and M&G plc. This financing has enabled them to expand their operations in Cambridge, UK and Boston, USA. As they move forward, Apollo Therapeutics aims to build on their existing collaborations, foster new relationships with additional top academics globally, and in-license drug candidates from new partners. For more information about Apollo Therapeutics, visit their website at www.apollotherapeutics.com

Funding Stage	Amount	Investors	Lead Investors	Date
Series C	$33.50M	3	Patient Square Capital, Rock Springs Capital +1	02 Jan 2024
Series C	£180.00M	3	Patient Square Capital, Rock Springs Capital +1	06 Sep 2023
Series B	£100.00M	4	Patient Square Capital, Rock Springs Capital +2	17 Jun 2021
Seed Round	Undisclosed	-		01 Jan 2017

Funding Stage

Amount

Investors

Lead Investors

Date

Series C

$33.50M

Patient Square Capital, Rock Springs Capital +1

02 Jan 2024

Series C

£180.00M

Patient Square Capital, Rock Springs Capital +1

06 Sep 2023

Series B

£100.00M

Patient Square Capital, Rock Springs Capital +2

17 Jun 2021

Seed Round

Undisclosed

01 Jan 2017

FAQ About Apollo Therapeutics

A transformative idea for transformative medicines

Apollo Therapeutics was founded in 2016.

Apollo Therapeutics operates in Biopharma, Biotechnology, Health Care and Health and Wellness. Its work centres on biopharmaceutical, therapeutic programs, drug development and pipeline.

Apollo Therapeutics has approximately 59 employees.

Apollo Therapeutics has completed 4 funding rounds, raising a total of $313.50M. The latest funding stage is Series C.

Top alternatives and competitors to Apollo Therapeutics include Adlai Nortye, AnnJi Pharmaceutical Co., Ltd., OnCusp Therapeutics, SFA Therapeutics, Zai Lab. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Apollo Therapeutics and Adlai Nortye are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Apollo Therapeutics

Funding Rounds & Investors (4)

Apollo Therapeutics Alternatives & Competitors

FAQ About Apollo Therapeutics